Diarrhea; White blisters on feet that itch; White blisters on feet that itch; itches and itched; all real deep red; Some blisters are more sore than others; booster; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 82 year-old female patient received bnt162b2 (BNT162B2), administered in arm right, administration date 14Oct2021 14:00 (Lot number: 301358A) at the age of 82 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Asthma" (ongoing), notes: Diagnosed since she was a child, maybe age 6-7 years old. It is severe asthma; "Osteoarthritis" (ongoing), notes: Non-curable, Had it for quite a long time , Arthritis doctor informed her she had obviously had this for quite a few years and didn't realize it. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (LOT: EP6955, Dose:1, Route: injected into right arm), administration date: 18Mar2021, when the patient was 82 years old, for COVID-19 immunization; Bnt162b2 (LOT: ER8731, Dose:2, Route: injected into right arm), administration date: 15Apr2021, when the patient was 82 years old, for COVID-19 immunization; Flu, administration date: Sep2021. The following information was reported: IMMUNISATION (non-serious) with onset 14Oct2021 14:00, outcome "unknown", described as "booster"; DIARRHOEA (non-serious) with onset 17Oct2021, outcome "recovered" (20Oct2021), described as "Diarrhea"; BLISTER (non-serious), LIMB DISCOMFORT (non-serious) all with onset 16Oct2021, outcome "not recovered" and all described as "White blisters on feet that itch"; PRURITUS (non-serious) with onset 16Oct2021, outcome "not recovered", described as "itches and itched"; ERYTHEMA (non-serious) with onset 16Oct2021, outcome "not recovered", described as "all real deep red"; PAIN (non-serious) with onset 16Oct2021, outcome "not recovered", described as "Some blisters are more sore than others". Therapeutic measures were taken as a result of blister, limb discomfort, pruritus, erythema, pain.  Additional information: Patient taking COVID-19 Vaccine (Verbatim) for age and severe asthma. Had the booster shot and two days after the shot started with three days of diarrhea. But also when diarrhea came, had a massive amount of white blisters on the bottom of feet and sides that itches and itched. Took it almost 3 weeks ago. Was told to report to Pfizer and that this could be a side effect that hasn't been reported before. Her feet still itch. Using double antibiotic cream and puts that on it. But where the blisters have been are all real deep red. Had no issues with the first two COVID-19 Vaccines. Reporter Details: Email: Declines. HCP Details: Declines. White blisters on feet that itch: On bottom, sides, and across the top of the feet where the toes connect. Also in the creases between the toes. Has been using a double antibiotic cream for the blisters and itching on her feet. Treatment: Has been using a double antibiotic cream. Was advised by the Pharmacist at # to use this to treat the blisters. States it slows down the itching, but the blisters come right back. The blisters pop. Some blisters are more sore than others. Treatment included: Bacitracin Zinc polymyxin b sulfate (Formulation: Double Antibiotic Ointment, NDC/LOT/EXP: Unknown and strength: 500 (Does not have any units of measurement)). Dose: Only uses it when it really gets to itching. Doesn't use it that much. Attempted to confirm spelling of product name with caller. When the spots itch really bad, she may let it go for a while. But then it gets bad and the ointment helps give the itch up. Confirmed it is a prescription product. Previous two doses administered at withheld. States she has never had anything like this. Time the vaccination of booster was given: afternoon about 2PM. It's right across the street from withheld. Withheld had Moderna and withheld had Pfizer. Wanted to stay with the one she started with. No emergency room and physician office visit. No Prior Vaccinations (within 4 weeks) to the first administration date of the suspect vaccine(s).